Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dworkin, R. H.
Right arrow Articles by Paty, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dworkin, R. H.
Right arrow Articles by Paty, D. W.
NEUROLOGY 1984;34:1441
© 1984 American Academy of Neurology

Linoleic acid and multiple sclerosis

A reanalysis of three double-blind trials

Robert H. Dworkin, PhD, David Bates, MD, FRCP, J.H.D. Millar, MD, FRCP and Donald W. Paty, MD, FRCP(C)

From the Department of Anesthesiology (Dr. Dworkin), College of Physicians and Surgeons, Columbia University, New York; Department of Neurology (Dr. Bates), Royal Victoria Infirmary, Newcastle upon Tyne, England; Department of Neurology (Dr. Millar), Royal Victoria and Claremont Street Hospitals, Belfast, Northern Ireland; and Division of Neurology (Dr. Paty), University of British Columbia, Vancouver, Canada.

Data from three double-blind trials of linoleic acid in the treatment of multiple sclerosis (MS) were reanalyzed to examine whether inconsistency in the results was due to a relationship between patient Characteristics and treatment response. The combined data consisted of neurologic assessments over 2/1,2-year trials for 87 treated patients and 85 control patients. Treated patients with minimal or no disability at entry had a smaller increase in disability than did controls (P < 0.05). In addition, treatment reduced the severity and duration of relapses at all levels of disability and duration of illness at entry to the trials.

Address correspondence and reprint requests to Dr. Dworkin, Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032.

Supported in part by the National Multiple Sclerosis Society.

Accepted for publication March 13, 1984.




This article has been cited by other articles:


Home page
Mult SclerHome page
S. Schwarz and H. Leweling
Multiple sclerosis and nutrition
Multiple Sclerosis, February 1, 2005; 11(1): 24 - 32.
[Abstract] [PDF]


Home page
NeurologyHome page
G. M. Franklin and L. Nelson
Environmental risk factors in multiple sclerosis: Causes, triggers, and patient autonomy
Neurology, October 28, 2003; 61(8): 1032 - 1034.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by AAN Enterprises, Inc.